A randomised phase II trial of a trivalent ganglioside vaccine targeting GM2, GD2 and GD3 combined with immunological adjuvant OPT-821 versus OPT-821 alone in metastatic sarcoma patients rendered disease-free by surgery
Year: 2022
Type: article
Study designs: Randomized Controlled Trial, Clinical Trial
Source: European Journal of Cancer
Authors: Evan Rosenbaum, Rashmi Chugh, Christopher W. Ryan, Mark Agulnik, Mohammed M. Milhem, Suzanne George, Robin L. Jones, Bartosz Chmielowski, Brian A. Van Tine, Hussein Tawbi, Anthony D. Elias, William L. Read, G. Thomas Budd, Li-Xuan Qin, Eve T. Rodler, Joe Hirman, Paul Weiden, Cathryn M. Bennett, Philip O. Livingston, Govind Ragupathi, David Hansen, Sandra P. D'Angelo, William D. Tap, Gary K. Schwartz, Robert G. Maki, Richard D. Carvajal
Institutions: Memorial Sloan Kettering Cancer Center, Weill Cornell Medical Center, University of Michigan, OHSU Knight Cancer Institute, City Of Hope National Medical Center, City of Hope, University of Iowa, University of Iowa Holden Comprehensive Cancer Center, Dana-Farber Cancer Institute, Institute of Cancer Research, University of Washington, Fred Hutch Cancer Center, University of California, Los Angeles, UCLA Jonsson Comprehensive Cancer Center, Washington University in St. Louis, The University of Texas MD Anderson Cancer Center, University of Colorado Cancer Center, Emory University, Cleveland Clinic, UC Davis Comprehensive Cancer Center, Mabvax Therapeutics (United States), Columbia University Irving Medical Center, Abramson Cancer Center, University of Pennsylvania
Language: English
Subfield: Pulmonary and Respiratory Medicine
Field: Medicine
Domain: Health Sciences
Open Access status: bronze
OpenAlex ID: W4303579729